Effect of a glutamate receptor antagonist (GYKI 52466) on 4-aminopyridine-induced seizure activity developed in rat cortical slices

Judit Dóczi, Ilona Banczerowski-Pelyhe, Barbara Barna, I. Világi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

In the present experiments we have tested the effect of the noncompetitive AMPA antagonist GYKI 52466 (20-80 μM) on spontaneous epileptic discharges developed as the consequence of 4-aminopyridine application in neocortex slices of adult rats. Parallel to the changes of spontaneous activity, the field potentials, evoked by electrical stimulation of the corpus callosum, were also analyzed. Glass microcapillary extracellular recording electrode was positioned in the third layer of the somatosensory cortex slice, while the stimulating electrode was placed at the border of the white and gray matter. 4-aminopyridine and GYKI 52466 were bath-applied. The application of 40 μM GYKI 52466 caused about 40% decrease in the frequency and the amplitude of spontaneous seizures as well as the duration of each discharges developed in 4-aminopyridine. Pre-incubation with the AMPA antagonist effectively inhibited both the development of seizure activity and the maintenance of the discharges. GYKI 52466 also decreased the duration and amplitude of field responses evoked by stimulation of the corpus callosum. This inhibitory effect was dose-dependent. Our data in the in vitro cortex slice epilepsy model suggest that the non-competitive AMPA antagonist GYKI 52466 is a potent anticonvulsant and neuroprotective compound because it reduced the fully developed epileptic discharges or prevented their development. Copyright (C) 1999 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)435-440
Number of pages6
JournalBrain Research Bulletin
Volume49
Issue number6
DOIs
Publication statusPublished - Aug 1999

Fingerprint

Excitatory Amino Acid Antagonists
4-Aminopyridine
Seizures
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Corpus Callosum
Electrodes
Somatosensory Cortex
Neocortex
Baths
Evoked Potentials
Anticonvulsants
Electric Stimulation
Glass
Epilepsy
Maintenance
GYKI 52466

Keywords

  • 4-Aminopyridine
  • Brain slice study
  • Epilepsy model
  • GYKI 52466
  • Microelectrophysiology

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Effect of a glutamate receptor antagonist (GYKI 52466) on 4-aminopyridine-induced seizure activity developed in rat cortical slices. / Dóczi, Judit; Banczerowski-Pelyhe, Ilona; Barna, Barbara; Világi, I.

In: Brain Research Bulletin, Vol. 49, No. 6, 08.1999, p. 435-440.

Research output: Contribution to journalArticle

@article{ada94794e3f946d4a73420b470924a8d,
title = "Effect of a glutamate receptor antagonist (GYKI 52466) on 4-aminopyridine-induced seizure activity developed in rat cortical slices",
abstract = "In the present experiments we have tested the effect of the noncompetitive AMPA antagonist GYKI 52466 (20-80 μM) on spontaneous epileptic discharges developed as the consequence of 4-aminopyridine application in neocortex slices of adult rats. Parallel to the changes of spontaneous activity, the field potentials, evoked by electrical stimulation of the corpus callosum, were also analyzed. Glass microcapillary extracellular recording electrode was positioned in the third layer of the somatosensory cortex slice, while the stimulating electrode was placed at the border of the white and gray matter. 4-aminopyridine and GYKI 52466 were bath-applied. The application of 40 μM GYKI 52466 caused about 40{\%} decrease in the frequency and the amplitude of spontaneous seizures as well as the duration of each discharges developed in 4-aminopyridine. Pre-incubation with the AMPA antagonist effectively inhibited both the development of seizure activity and the maintenance of the discharges. GYKI 52466 also decreased the duration and amplitude of field responses evoked by stimulation of the corpus callosum. This inhibitory effect was dose-dependent. Our data in the in vitro cortex slice epilepsy model suggest that the non-competitive AMPA antagonist GYKI 52466 is a potent anticonvulsant and neuroprotective compound because it reduced the fully developed epileptic discharges or prevented their development. Copyright (C) 1999 Elsevier Science Inc.",
keywords = "4-Aminopyridine, Brain slice study, Epilepsy model, GYKI 52466, Microelectrophysiology",
author = "Judit D{\'o}czi and Ilona Banczerowski-Pelyhe and Barbara Barna and I. Vil{\'a}gi",
year = "1999",
month = "8",
doi = "10.1016/S0361-9230(99)00079-9",
language = "English",
volume = "49",
pages = "435--440",
journal = "Brain Research Bulletin",
issn = "0361-9230",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Effect of a glutamate receptor antagonist (GYKI 52466) on 4-aminopyridine-induced seizure activity developed in rat cortical slices

AU - Dóczi, Judit

AU - Banczerowski-Pelyhe, Ilona

AU - Barna, Barbara

AU - Világi, I.

PY - 1999/8

Y1 - 1999/8

N2 - In the present experiments we have tested the effect of the noncompetitive AMPA antagonist GYKI 52466 (20-80 μM) on spontaneous epileptic discharges developed as the consequence of 4-aminopyridine application in neocortex slices of adult rats. Parallel to the changes of spontaneous activity, the field potentials, evoked by electrical stimulation of the corpus callosum, were also analyzed. Glass microcapillary extracellular recording electrode was positioned in the third layer of the somatosensory cortex slice, while the stimulating electrode was placed at the border of the white and gray matter. 4-aminopyridine and GYKI 52466 were bath-applied. The application of 40 μM GYKI 52466 caused about 40% decrease in the frequency and the amplitude of spontaneous seizures as well as the duration of each discharges developed in 4-aminopyridine. Pre-incubation with the AMPA antagonist effectively inhibited both the development of seizure activity and the maintenance of the discharges. GYKI 52466 also decreased the duration and amplitude of field responses evoked by stimulation of the corpus callosum. This inhibitory effect was dose-dependent. Our data in the in vitro cortex slice epilepsy model suggest that the non-competitive AMPA antagonist GYKI 52466 is a potent anticonvulsant and neuroprotective compound because it reduced the fully developed epileptic discharges or prevented their development. Copyright (C) 1999 Elsevier Science Inc.

AB - In the present experiments we have tested the effect of the noncompetitive AMPA antagonist GYKI 52466 (20-80 μM) on spontaneous epileptic discharges developed as the consequence of 4-aminopyridine application in neocortex slices of adult rats. Parallel to the changes of spontaneous activity, the field potentials, evoked by electrical stimulation of the corpus callosum, were also analyzed. Glass microcapillary extracellular recording electrode was positioned in the third layer of the somatosensory cortex slice, while the stimulating electrode was placed at the border of the white and gray matter. 4-aminopyridine and GYKI 52466 were bath-applied. The application of 40 μM GYKI 52466 caused about 40% decrease in the frequency and the amplitude of spontaneous seizures as well as the duration of each discharges developed in 4-aminopyridine. Pre-incubation with the AMPA antagonist effectively inhibited both the development of seizure activity and the maintenance of the discharges. GYKI 52466 also decreased the duration and amplitude of field responses evoked by stimulation of the corpus callosum. This inhibitory effect was dose-dependent. Our data in the in vitro cortex slice epilepsy model suggest that the non-competitive AMPA antagonist GYKI 52466 is a potent anticonvulsant and neuroprotective compound because it reduced the fully developed epileptic discharges or prevented their development. Copyright (C) 1999 Elsevier Science Inc.

KW - 4-Aminopyridine

KW - Brain slice study

KW - Epilepsy model

KW - GYKI 52466

KW - Microelectrophysiology

UR - http://www.scopus.com/inward/record.url?scp=0033180438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033180438&partnerID=8YFLogxK

U2 - 10.1016/S0361-9230(99)00079-9

DO - 10.1016/S0361-9230(99)00079-9

M3 - Article

VL - 49

SP - 435

EP - 440

JO - Brain Research Bulletin

JF - Brain Research Bulletin

SN - 0361-9230

IS - 6

ER -